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€ 42,600/QALY for payers. ConClusions: All the estimated ICER values were higher 
than the thresholds usually described in the literature (€ 20,000-30,000/QALY), with 
relevant differences among the groups. In both scenarios, payers were less prone 
to pay for therapeutic improvements compared to the rest of the participants. On 
the other hand, oncologists were the ones that most valued gains in survival for 
a new treatment while patients assigned a higher value for money to a treatment 
that enhanced the quality of life.
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objeCtives: The purpose of this study is to evaluate the impact of cost-effec-
tiveness and disease severity on the drug reimbursement decisions made by the 
reimbursement agency TLV in Sweden. Methods: Cost-effectiveness is measured 
through the continuous variable cost per QALY, while disease severity is meas-
ured by a dichotomous variable indicating high- or not high disease severity. We 
analyze all reimbursement decisions from 2005 through 2011 where there is data 
available on cost per QALY and disease severity. Logistic regressions are used to 
evaluate the impact of cost-effectiveness and disease severity on the drug reim-
bursement decisions. Results: There are 102 decisions with the required data 
available, 86 where reimbursement was granted and 16 where reimbursement was 
denied. The median cost per QALY for the drugs that were granted reimbursement 
was 39 000 euro (9sek/euro), ranging from a negative cost per QALY (better and 
cheaper) to 136 000 euro. The median cost per QALY for the drugs that were denied 
reimbursement was 111 000 euro, ranging from 78 000 euro to 1 111 000 euro. The 
results from the logistic regression analysis show that both the cost per QALY and 
the level of disease severity are statistically significantly related to the probability 
of a drug being granted reimbursement. When the cost per QALY exceeds 56 000 
euro for non-severe diseases, and 92 000 euro for severe diseases, the probability 
that reimbursement is denied is higher than the probability that reimbursement 
is granted. ConClusions: In Sweden, it is sometimes stated as a rule of thumb 
that 55 000 euro per QALY is a threshold for cost-effective interventions. Our model 
shows that at this cost-effectiveness ratio, the probability of a new drug becoming 
reimbursed is 91 % or 98 %, depending on disease severity.
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objeCtives: The aim of the study was to assess the comparative efficacy of rec-
ommended treatment for chronic heart failure with reduced ejection fraction in 
terms of all-cause mortality based on a network met-analysis (NMA) of randomized 
controlled trials (RCTs) and to explore the impact of alternative treatment classifi-
cations depending on concomitant treatments. Methods: A systematic literature 
search identified 56 relevant RCTs (1980-2013) that reported mortality data that 
were synthesized using a Bayesian Poisson regression NMA model. Treatments 
were classified as angiotensin converting enzyme inhibitors (ACEI), beta-blockers 
(BB), angiotensin II receptor blockers (ARB), mineralocorticoid/aldosterone receptor 
antagonists (MRA) and the Ifchannel inhibitor (IF) ivabradine. Analysis 1 classified 
treatments according to the main drugs of interest, whereas Analysis 2 defined 
treatments according to the main drugs of interest as well as the concomitant 
treatments belonging to classes of interest if more than 50% of patients were tak-
ing concomitant drugs. Results: Six regimens were compared in Analysis 1 and 
10 regimens were compared in Analysis 2. Analysis 1 resulted in the following rate 
ratios (RR) versus placebo: ACEI: 0.81 (95% Credible Interval 0.61, 0.95); BB: 0.71 (0.60, 
0.80); ARB: 0.90 (0.75, 1.02); ACEI+BB: 0.48 (0.30, 0.76). Analysis 2 resulted in the fol-
lowing RRs versus placebo: ACEI: 0.81 (0.68, 0.95); BB: 0.57 (0.35, 0.87); ARB: 0.81 (0.61, 
1.01); ACEI+BB: 0.61 (0.54, 0.68). The treatments that are expected to be most effica-
cious depended on the treatment classification: Analysis 1 supported ACEI+BB and 
BB, whereas Analysis 2 supported ACEI+BB+MRA+IF and ACEI+BB+MRA [RR: 0.44 
(0.34, 0.58) and 0.48 (0.38, 0.60), respectively]. ConClusions: Combination treat-
ments were likely to be more efficacious than monotherapy and adding a class to a 
regimen was likely to make it more efficacious regardless of the approach. However, 
treatment classifications affect the results and interpretation. The approach that 
accounts for concomitant treatments is preferred.
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objeCtives: Children have been termed “therapeutic orphans” due to the paucity 
of age-specific therapeutic data. Here we review the extent to which utility data 
derived from under-18s were used to inform National Institute for Health and Care 
Excellence (NICE) Technology Appraisals (TAs) providing cost-effectiveness guid-
ance in paediatric indications, in line with the NICE reference case. Methods: 
All 311 published TAs up to April 2014 were initially sifted to identify therapeu-
tic recommendations for children. Identified TAs were reviewed to determine if a 
cost-utility analysis (CUA) was performed. For each CUA, the published TA along 
with the manufacturer’s submission (single TAs) or the assessment report (multiple 
TAs) were examined to determine the origin of the utilities used. Results: Of 35 
published TAs reviewed, 27 analysed cost-per-QALY and made recommendations 
for treatment of under-18s. Of these, 17 used adult utilities, 1 of which attempted 
to adjust the adult values for children; 3 considered child and adult populations 
as one, with child-derived data used within the overall model inputs for the whole 
population, 1 of which adjusted both child and adult utilities by age. Only 6 studies 
used child-specific utilities: 1 assumed a specified change from treatment on a 
generic QoL instrument, 2 used parent-reported utilities on a generic QoL instru-
ment, 1 used parent-reported utilities mapped from a disease-specific scale and 
2 used child-reported utilities mapped from a disease-specific scale. One MTA 
contained diverging submissions, 1 adult-derived and 1 child-reported. No trends 
over time in the types of utilities used were apparent from visual examination of 
the results. ConClusions: Despite NICE’s reference case specifying that utilities 
should be measured in the population in question, children may also be termed 
“economic orphans” with the majority of cost-utility submissions applying adult-
derived utilities to paediatric indications and no trend away from this apparent 
over time.
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objeCtives: To explore the impact of different utility measurement strategies on the 
results of a cost-effectiveness analysis, funding decisions, decision uncertainty and 
value of information. Methods: Data from a UK trial of two cancer therapies (active 
versus standard care) were analysed using NICE reference case methods. Within-trial, 
cost-utility analyses were conducted with utility based on a number of strategies: A) 
Observed EQ-5D; cancer-specific utility based on the EORTC QLQ-C30 B) the EORTC-8D 
and C) the QLQ_U; Mapping from QLQ-C30 to EQ-5D using an algorithm generated 
in D) the same cancer patient group and E) a different cancer group. Incremental 
cost-effectiveness ratios (ICERS) were calculated. Bootstrapped net benefit estimates 
allowed generation of cost-effectiveness acceptability curves (CEACs) and popula-
tion expected value of perfect information (EVPI) was calculated using incremental 
cost scenarios. Results were compared across utility strategies. Results: There were 
small but important differences observed in the incremental QALYs which ranged 
from 0.067 (EQ-5D) to 0.036 (EORTC-8D). Large differences were observed in the ICERs 
generated; for strategies A to E these were: £57,513; £106,264; £102,785; £90,049; 
£78,885. Using an incremental cost scenario of £3,000 only strategy A yielded an ICER 
< £30,000. At a QALY willingness to pay threshold (WTPT) of £20,000 there was little 
decision uncertainty. However, assuming WTPT= £50,000, the probability the active 
treatment was cost-effective ranged 0.34 (EQ-5D) to 0.025 (EORTC-8D). Using this 
threshold, the population EVPI for the strategies were: £3,597,844; £120,621; £155,858; 
£354,094; £805,847. ConClusions: Different utility sources can lead to very different 
estimates of cost-effectiveness and value of further research and change funding 
decisions. Estimates of cost-effectiveness based on mapping (even when the algo-
rithm appears to perform well) can differ substantively from those based on observed 
scores. The lowest ICERs were obtained with the EQ-5D but this may not capture 
side-effects picked up by the cancer-specific utility measures.
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objeCtives: To analyze oncologists’, payers’, patients’, and general population´ 
views on the cost and value of new cancer treatments. Methods: An electronic 
self-administered questionnaire was developed and randomly distributed, to assess 
participants’ attitudes towards new cancer treatment outcomes and costs dur-
ing reimbursement decisions. Among the questions asked were two hypothetical 
scenarios. First, participants were asked to indicate the minimum survival benefit 
that a new treatment, that cost € 50,000 more than the standard therapy, should 
have to be funded by the Spanish National Health System (NHS). Second, partici-
pants were requested to state the highest costs to be afforded by the NHS for a 
medication increasing patient’s quality of life (QoL) twofold with no changes in 
survival. Responses were used to calculate incremental cost-effectiveness ratios 
(ICER). Results: 53 oncologists, 60 patients, 25 payers, and 50 individuals from gen-
eral population answered the questionnaire. The minimum improvement median 
in patient survival that justified the inclusion into the NHS was 5.66 months for 
oncologists, 8.16 for patients, 9.08 for general population and 10.44 for payers; 
implying different ICER for oncologists (€ 106,000/QALY), patients (€ 73,520/QALY), 
general population (€ 66,074/QALY) and payers (€ 57,471/QALY). The cost stated in 
QoL-enhancing scenario was € 33,167 for patients, € 30,200 for general population, 
€ 26,000 for oncologists and € 17,040 for payers; resulting in ICERs of € 82,917/QALY 
for patients, € 75,500/QALY for general population, € 65,000/QALY for oncologists, and 
